Esophagectomy for cancer:

Slides:



Advertisements
Similar presentations
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
Advertisements

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Failure of Treatment in Cervical Cancer Patients *Dr. Zohreh Yousefi fellow ship of gynecology oncology of Mashhad university Fatemeh Homaee, Marzieh.
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
The significance of extracapsular lymph node involvement in node- positive patients with adenocarcinoma of the distal oesophagus or gastro-oesophageal.
J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer NEJM July vol 359 R2 임규성.
Fig. 1: Regional abdominal lymph node dissection during 2-field LND. Fig. 2: full mobilisation of spleen and pancreatic tail to allow complete LND of.
Oesophago–Gastric Cancer Audit
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Perioperative Complications after Neoadjuvant Chemoradiation for Locally-Advanced Esophageal Cancer: A Comparison of Platinum/5-FU and Carboplatin/Paclitaxel.
Comparison Between Definitive Chemoradiotherapy and Esophagectomy in Patients With Clinical Stage I Esophageal Squamous Cell Carcinoma Sachiko Yamamoto MD,
Short-term outcome of neo-adjuvant chemotherapy
Oesophago–Gastric Cancer
Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Title Introduction Methods Results Discussion Authors
Clinicopathological features and outcome of Head & Neck Cancer in Pakistan 1A Jamshed, 1R Hussain, 2S Jamshed, 1A A Syed, 1A Loya, 1M A Shah, 1U Majeed.
1 LINFOADENECTOMIA Alessandro Volpe Università del Piemonte Orientale
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
Results of surgical treatment of adenocarcinoma of the gastric cardia
A Hussain, S Qadri, Y Haqzad, M Chaudhry, A Cale, M Cowen, M Loubani.
Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.
Compassionate People World Class Care
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
Prognosis of younger patients in non-small cell lung cancer
5-YEAR SURVIVAL OF UPPER THIRD ESOPHAGEAL CANCER PATIENTS WAS SIGNIFICANTLY SUPERIOR IN COMPARISON WITH MIDDLE AND LOWER THIRD ESOPHAGEAL CANCER PATIENTS.
HEPATIC RESECTION FOR PARENCHIMATOUS OVARIAN CANCER LIVER METASTASES BEYOND SECONDARY CYTOREDUCTION FOR RELPASED OVARIAN CANCER Nicolae Bacalbasa1,
以單孔方式進行再次胸腔鏡手術做主要肺切除的可行性 The Feasibility of Major Lung Resection in Repeated Video-Assisted Thoracoscopic Surgery (VATS) by Single-Port Approach Ying-Yuan.
Laparoscopic vs Open Colonic Surgery: Long Term Survival
Advancing Gynaecological Surgery:
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
HEART-LUNG TRANSPLANTATION
HEART TRANSPLANTATION
Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis  Amgad El-Sherif, MD, William E. Gooding, MS,
Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
HEART-LUNG TRANSPLANTATION
Factors predictive of prognosis after esophagectomy for squamous cell cancer  Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.
Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,
Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,
Appraisal of a Revised Lymph Node Classification System for Esophageal Squamous Cell Cancer  Dipok Kumar Dhar, PhD, Shinji Hattori, MD, Yasuhito Tonomoto,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
HEART-LUNG TRANSPLANTATION
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma  Chen-Sung Lin, MD, PhD, Chih-Tao Cheng, MD, DrPH, Chao-Yu.
Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E
Comparison of the 6th and 7th Editions of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System in Patients With Resected Esophageal.
Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases  Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.
Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.
Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD 
HEART-LUNG TRANSPLANTATION
Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.
It’s All in the “Swerve of the Curve”
A Strategy for Determining Which Thoracic Esophageal Cancer Patients Should Undergo Cervical Lymph Node Dissection  Shiro Nagatani, MD, Yutaka Shimada,
Primary Small Cell Carcinoma of the Esophagus
James D Luketich, Michael E Burt  The Annals of Thoracic Surgery 
Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors  Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.
Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer  Steven M Keller, MD, Sudeshna Adak,
Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer  Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.
HEART-LUNG TRANSPLANTATION
Presentation transcript:

Esophagectomy for cancer: Surgeon case volume may be more important than hospital volume for good quality of outcome INTRODUCTION Georges Decker, Hélène Groot Koerkamp Centre de Chirurgie Tumorale, ZithaKlinik Luxembourg 36, rue Sainte Zithe L-2763 Luxembourg Georges.Decker@zitha.lu Introduction: Esophagectomy for cancer is considered to be one of the operations with the strongest volume-outcome relationships. Numerous studies have shown that so-called "high-volume" hospitals achieve lower mortality&morbidity rates but also better oncological outcome than "low-volume" hospitals. However, the definitions and ideal volume cut-offs remain controversial and the real determinants of good quality of care in esophageal cancer surgery remain to be defined. These determinants are important to be found since worldwide in many areas, "centralisation" may not be a realistic option. Methods: We retrospectively analysed the outcome of 63 primary esophagectomies for esophageal cancer performed by a single surgeon between 2002 and 2011 in 2 subsequent "low-volume” hospitals in Luxembourg (34 resections over 7 years at Centre Hospitalier Luxembourg followed by 29 resections over 5 years at Zithaklinik, figure 1). This analysis excludes 8 esophagectomies performed during the same time period for other indications: benign diseases (6), salvage esophagectomies after definitive chemo-radiation (2). Both hospitals in Luxembourg were "low-volume" hospitals (less than 10 resections per year) as no other surgeon had performed any esophagectomy in these hospitals during the same time period. However, the surgeon was a "high-volume" surgeon as during the same time period, he had also performed more than 190 cancer esophagectomies in a University hospital in Belgium (UZ-Leuven). Results: Sixty-three patients underwent subtotal esophagectomy with partial gastrectomy and radical lymph node dissection (LND): 2 field LND in 56 patients, 3-field LND in 7 patients (11%). Median age was 65 years (36-83). Induction chemo- or chemo-radiotherapy was administered in 14% of patients. Tumor histology was squamous cell cancer in 27% and adenocarcinoma in 71%. All patients, except for one transhiatal resection, underwent trans-thoracic resections. The majority of procedures were performed by a left thoraco-abdominal approach with cervical anastomosis. Overall, 58 patients (92%) had their anastomosis in the neck. Median operative time was 400 minutes (243-590). Median blood loss was 380 ml (185-1000) and peri-operative transfusion rate was 27%. Fifty-three patients (84%) were extubated in the OR at the end of the operation. Overall 30-day mortality was 1.6% due to respiratory failure in one patient (day 22). 90-day mortality rate was 3.2% as one patient died from fulgurant metastatic tumor progression after 66 days. Prospective complication assessment found deviations from the ideal protocol in 67% of patients and reoperations in 11% of patients. Overall post-operative hospital stay was 19 days (9-121), being 20 days in the first hospital versus 16 days in the second hospital (p=0.77). Complete resection (R0) was obtained in 92% of patients. A median of 37 lymph nodes (8-69) were examined per patient. Forty-three patients (68%) were pN+ as they had at least one lymph node involved by tumor (median 2 positive nodes, range 1-29). After a median follow-up of 23 months (2.5-121), respectively 33 months (7-121) for the survivors, overall median survival was 38 months (mean survival of 65 months). Five and 10-year survival probabilities were 47% respectively 43%, despite the fact that 65% of all patients were in pTNM stages 3 or 4. 5-year survival for stage p3A patients (TNM 7th edition) was 53%. Mean survival for N0 patients was 83 months, compared to 49 months for N+ patients. Estimated 5-year survival for N+ patients was 41% versus 63% for N0 patients (log Rank test p=0.038). Conclusion: For cancer esophagectomy, the individual surgeon's training and experience may be a much more important determinant of outcome than "hospital volumes”. “Low-volume" hospitals with adequate organization and equipment can achieve surgical and oncological outcome at least similar to large tertiary referral centers. 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Figure 1: Annual case load of esophageal cancer resections Figure 2: Overall Kaplan-Meier survival curve Figure 3: Survival curve comparison N0 versus N+ patients, log rank test p=0.038 Figure 4: pTNM stages (7th edition 2009)